Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates

Leukemia and Lymphoma

Volumn 56, Issue 8, 2015, Pages 2373-2378

  Zent, Clive S ^a   Call, Timothy G ^a   Bowen, Deborah A ^a   Conte, Michael J ^a   LaPlant, Betsy R ^b   Witzig, Thomas E ^a   Ansell, Stephen M ^a   Weiner, George J ^c  

^a Div Hematol Oncol Blood M   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

alemtuzumab; Chronic lymphocytic leukemia small lymphocytic lymphoma; CLL; high risk; PGG beta glucan; rituximab

Indexed keywords

ALEMTUZUMAB; BETA GLUCAN; CYCLOPHOSPHAMIDE; FLUDARABINE; METHYLPREDNISOLONE; POLY [1-6] BETA GLUCOTRIOSYL [1-3] BETA GLUCOPYRANOSE BETA GLUCAN; RITUXIMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VALGANCICLOVIR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFUSION RELATED REACTION; LEUKEMIA REMISSION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; CHROMOSOME ABERRATION; CLINICAL TRIAL; DISEASE COURSE; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; REMISSION; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA-GLUCANS; BIOMARKERS, TUMOR; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; REMISSION INDUCTION; RITUXIMAB; TREATMENT OUTCOME;

EID: 84943379790     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1016932     Document Type: Article

References (18)

1. Faderl S, Thomas DA, OBrien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101: 3413-3415.
2. Nabhan C, Patton D, Gordon L, et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004; 45: 2269-2273.
3. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab and rituximab Cancer 2008; 113: 2110-2118.
4. Zent CS, Wu W, Bowen DA, et al. Addition of GM-CSF does not improve response to early treatment of high risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma 2013; 54: 476-482.
5. Frankfurt O, Ma S, Gordon L, et al. Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short-and long-term outcomes. Leuk Lymphoma 2015; 56: 315-323.
6. Taylor RP, Lindorfer MA. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol Pharmacol 2014; 86: 485-491.
7. Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 2012; 526: 146-153.
8. Chan GC, Chan WK, Sze DM. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol 2009; 2: 25.
9. Li B, Allendorf DJ, Hansen R, et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol 2006; 177: 1661-1669.
10. Hong F, Hansen RD, Yan J, et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 2003; 63: 9023-9031.
11. Li B, Allendorf DJ, Hansen R, et al. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res 2007; 67: 7421-7430.
12. Hoogeboom R, van Kessel KP, Hochstenbach F, et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 2013; 210: 59-70.
13. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008; 111: 5446-5456.
14. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
15. Sargent DJ, Chan V, Goldberg RM. A three-outcome design for phase II clinical trials. Control Clin Trials 2001; 22: 117-125.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35.
18. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.